View Older Stories
-
Lilly's Taltz and Zepbound combo shows broader biomarker changes
-
Eli Lilly (LLY) PT Raised to $1,440 at Cantor Fitzgerald - Consensus Numbers Above Top-Line Guide
-
FDA approves Lilly's Jaypirca for first-line CLL/SLL treatment
-
Wedbush Downgrades Foghorn Therapeutics (FHTX) to Neutral
-
BMO Capital on Eli Lilly (LLY): 'TRIUMPHant Return'
-
Lilly obesity pill linked to lower predicted diabetes, heart disease risk
-
BTIG survey finds GLP-1 users cut 500 calories daily from diet
-
Lilly's oral GLP-1 pill shows CV safety in large diabetes trial
-
Trump praises Lilly, Merck, Pfizer investments
-
Lilly's EloraTZP shows greater weight loss than tirzepatide in Phase 2b trial
-
Lilly's Ebglyss meets endpoints in hand and foot eczema trial
-
Lilly study links Zepbound to more weight loss than Wegovy HD
-
Lilly's orforglipron shows edge over oral semaglutide 25 mg in analysis
-
Eli Lilly & Co. (LLY) CEO sees company doing more deals in untapped areas
-
CMS pumps $51M into rural Texas to fight diabetes and obesity
-
Eli Lilly (LLY) PT Raised to $1,500 at JPMorgan as Guidance Raise Expected
-
Lilly launches access initiative for diabetes drugs in low-income countries
-
China clears Jaypirca for CLL/SLL across all treatment lines
-
Nektar wins $90M verdict against Eli Lilly in contract dispute
-
FDA approves Lilly's once-weekly basal insulin for type 2 diabetes
-
Roche obesity drug shows 15.5% weight loss in diabetes trial
-
TD Cowen Reiterates Buy Rating on Eli Lilly (LLY)
-
Lilly breaks ground on $6.5B Houston drug manufacturing site
-
Eli Lilly (LLY) PT Raised to $1,284 at Guggenheim
-
Berenberg Upgrades Eli Lilly (LLY) to Buy
-
Berenberg Upgrades Eli Lilly (LLY) to Buy
-
BMO Capital on Eli Lilly's (LLY) Positioning for 2H26
-
Bessent at Charlotte Private Luncheon warns China AI win would 'negate all else', targets 80% compute share by 2028
-
JPMorgan Reiterates Overweight Rating on Eli Lilly (LLY)
-
BMO Capital: 'Eli Lilly (LLY) to Acquire Precision I&I Biotech Merida Bio'
-
Lilly reports one-year data on Taltz and Zepbound combined in psoriatic disease
-
Novo Nordisk seeks China approval for oral Wegovy drug
-
Lilly study links Zepbound to lower costs in adults over 55
-
PepsiCo Scraps Coverage of Weight-Loss Drugs for Employees - Bloomberg
-
Amplitude Therapeutics signs taRNA vaccine deal with Eli Lilly
-
Morgan Stanley analysts visit National Resilience facility in Ohio, clients include LLY and AZN
-
Lilly files six lawsuits over illegal sales of unapproved retatrutide
-
Eli Lilly selects Veeva Vault CRM for global deployment
-
BofA raises obesity market forecast on Lilly stock international strength
-
Eli Lilly (LLY) PT Raised to $1,330 at Wells Fargo
-
Eli Lilly (LLY) PT Raised to $1,400 at BMO Capital
-
Eli Lilly shares pop as weight-loss drug demand fuels guidance hike
-
Eli Lilly & Co. (LLY) Misses Q2 EPS by 46c ; Offers Guidance
-
Earnings preview: Bernstein sees ‘clear potential for further upside’ in this stock
-
Eli Lilly & Co. (LLY) call put ratio 1 call to 1.4 puts into quarter results
-
Eli Lilly & Co. (LLY) call put ratio 1 call to 1 put into quarter results
-
Eli Lilly & Co. (LLY) call put ratio 1 call to 1.5 puts with into quarter results
-
FDA grants Lilly's olomorasib breakthrough therapy status for pancreatic cancer
-
U.S. biopharma earnings: Eli Lilly (LLY), Pfizer (PFE) take the stage
-
Eli Lilly and Resilience to invest $750 million in US manufacturing


